Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity
Author
Abstract
Suggested Citation
DOI: 10.1038/s41467-024-50474-y
Download full text from publisher
References listed on IDEAS
- Cheng-Tao Jiang & Kai-Ge Chen & An Liu & Hua Huang & Ya-Nan Fan & Dong-Kun Zhao & Qian-Ni Ye & Hou-Bing Zhang & Cong-Fei Xu & Song Shen & Meng-Hua Xiong & Jin-Zhi Du & Xian-Zhu Yang & Jun Wang, 2021. "Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
- Xinyue Qi & Fanlin Li & Yi Wu & Chen Cheng & Ping Han & Jieyi Wang & Xuanming Yang, 2019. "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity," Nature Communications, Nature, vol. 10(1), pages 1-11, December.
- Olivier Demaria & Stéphanie Cornen & Marc Daëron & Yannis Morel & Ruslan Medzhitov & Eric Vivier, 2019. "Publisher Correction: Harnessing innate immunity in cancer therapy," Nature, Nature, vol. 576(7785), pages 3-3, December.
- Edward Seung & Zhen Xing & Lan Wu & Ercole Rao & Virna Cortez-Retamozo & Beatriz Ospina & Liqing Chen & Christian Beil & Zhili Song & Bailin Zhang & Mikhail Levit & Gejing Deng & Andrew Hebert & Patri, 2022. "A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells," Nature, Nature, vol. 603(7900), pages 328-334, March.
- Olivier Demaria & Stéphanie Cornen & Marc Daëron & Yannis Morel & Ruslan Medzhitov & Eric Vivier, 2019. "Harnessing innate immunity in cancer therapy," Nature, Nature, vol. 574(7776), pages 45-56, October.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Mengxue Zhou & Jiaxin Wang & Jiaxing Pan & Hui Wang & Lujia Huang & Bo Hou & Yi Lai & Fengyang Wang & Qingxiang Guan & Feng Wang & Zhiai Xu & Haijun Yu, 2023. "Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Katrin Rabold & Martijn Zoodsma & Inge Grondman & Yunus Kuijpers & Manita Bremmers & Martin Jaeger & Bowen Zhang & Willemijn Hobo & Han J. Bonenkamp & Johannes H. W. Wilt & Marcel J. R. Janssen & Lenn, 2022. "Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
- Eric H. Bent & Luis R. Millán-Barea & Iris Zhuang & Daniel R. Goulet & Julia Fröse & Michael T. Hemann, 2021. "Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
- Yuedong Guo & Qunqun Bao & Ping Hu & Jianlin Shi, 2023. "Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
- Yu-Hsuan Chen & Han-Hsiun Chen & Won-Jing Wang & Hsin-Yi Chen & Wei-Syun Huang & Chien-Han Kao & Sin-Rong Lee & Nai Yang Yeat & Ruei-Liang Yan & Shu-Jou Chan & Kuen-Phon Wu & Ruey-Hwa Chen, 2023. "TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
- Caihua Zhang & Kang Li & Hongzhang Zhu & Maosheng Cheng & Shuang Chen & Rongsong Ling & Cheng Wang & Demeng Chen, 2024. "ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
- Joseph R. Palmeri & Brianna M. Lax & Joshua M. Peters & Lauren Duhamel & Jordan A. Stinson & Luciano Santollani & Emi A. Lutz & William Pinney & Bryan D. Bryson & K. Dane Wittrup, 2024. "CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
- Yue Wang & Shi-Kun Zhou & Yan Wang & Zi-Dong Lu & Yue Zhang & Cong-Fei Xu & Jun Wang, 2023. "Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
- Ziyang Cao & Dongdong Li & Liang Zhao & Mengting Liu & Pengyue Ma & Yingli Luo & Xianzhu Yang, 2022. "Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50474-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.